Skip to content

Efficacy of time restricted eating and economic behavioral intervention in reducing fasting plasma glucose, HbA1c, and cardiometabolic risk factors compared to time restricted eating alone or usual care in patients with prediabetes: A randomized controlled trial

Efficacy of time restricted eating and economic behavioral intervention in reducing fasting plasma glucose, HbA1c, and cardiometabolic risk factors compared to time restricted eating alone or usual care in patients with prediabetes: A randomized controlled trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210520002
Enrollment
114
Registered
2021-05-20
Start date
2021-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired fasting glucose Time restricted eating impaired glucose tolerence

Interventions

Time restricted eating refers to limitation of the daily time of food intakes to 9 hours and then is resulted in prolong fating in the night time to 15 hours. Participants will be requested to limit t
Time restricted eating with behavioral economic intervention ,Time restricted eating ,Usual care

Sponsors

National Research Council of Thailand (NRCT)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: impaired fasting glucose (100-125 mg/dL) or abnormal HbA1c (5.7-6.49%) age 18-65 years BMI more than 25 kg/m2

Exclusion criteria

Exclusion criteria: 1. Currently on ketogenic diet or vegeterian diet 2. Currently on TRE 3. Shift work 4. Weight change more than 5 kg in 3 months 5. Having medication which has to be taken at early morning or at night 6. Smoking 7. Breast feeding 8. Psychological disorder excluding depression 9. Having medications which affect weight and blood sugar 10. History of bariatric surgery 11. Impaired nutrient absorption

Design outcomes

Primary

MeasureTime frame
Fasting blood sugar 4,8,12 weeks hexokinase glucose-6 phosphate dehydrogenase and turbid metric inhibition immunoassay ,HbA1C 4,8,12 weeks hexokinase glucose-6 phosphate dehydrogenase and turbid metric inhibition immunoassay

Secondary

MeasureTime frame
Body weight 4,8,12 weeks weight measurement (kg) ,Systolic blood pressure 4,8,12 weeks mmHg,Diastolic blood pressure 4,8,12 weeks mmHg,Fasting insulin 4,8,12 weeks mIU/mL,serum triglyceride 4,8,12 weeks mg/dL ,Total cholesterol 4,8,12 weeks mg/dL,LDL-C 4,8,12 weeks mg/dL,HDL-C 4,8,12 weeks mg/dL ,high sensitivity C-reactive protein 4,8,12 weeks mg/dL

Countries

Thailand

Contacts

Public ContactUnyaporn Suthutvoravut

Mahidol University

unyaporn.s@gmail.com0869041556

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026